Literature DB >> 3534054

Effect of disease states on theophylline elimination.

J W Jenne.   

Abstract

Host factors play an important role in the dosing requirements of theophylline. Theophylline metabolism and clearance depend principally on liver cell function rather than on hepatic flow. The effects of acute hypoxemia require more study; however, patients with chronic obstructive pulmonary disease who have chronic hypoxemia appear to have some impairment of clearance. Clearance is variably and sometimes drastically reduced in patients with liver disease and heart failure, and is reduced by some viral infections. It is not impaired by renal failure. Current split-virus vaccine mixtures do not appear to affect clearance. Clearance is increased in patients with cystic fibrosis and hyperthyroidism. The depressed clearance seen in the severely ill patients who require intensive care improves with improvement in the patient's condition, but the individual factors involved have not been identified. An area requiring more study is the effect of pH on the apparent distribution volume for theophylline. In the presence of liver disease, heart failure, or serious illness, caution must be applied in theophylline dosing, with frequent monitoring of serum levels. Stable patients also warrant an initially conservative dose until serum levels are obtained to guide further dose adjustments.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534054     DOI: 10.1016/0091-6749(86)90053-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  4 in total

1.  The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.

Authors:  J Kraan; J H Jonkman; G H Koëter; C H Gips; P E de Jong; T W van der Mark; I Ekman; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  The pharmacological approach to the elderly COPD patient.

Authors:  Timothy E Albertson; Michael Schivo; Amir A Zeki; Samuel Louie; Mark E Sutter; Mark Avdalovic; Andrew L Chan
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

Review 3.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 4.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.